July 25, 2011
In this week’s installment of highlighting investment opportunities, today, I’m going to cover ImmunoCellular Therapeutics (IMUC). Background ImmunoCellular Therapeutics is a California-based oncology firm with the lead candidate ICT-107 entering Phase II for patients with a particular form of brain cancer, glioblastoma multiforme (GBM). IMUC’s primary candidate targets cancer stem cells via a dendritic cell-based […]
Read the full article →
July 17, 2011
This weekend, BusinessWeek did a comprehensive piece on the decline of the actively managed mutual fund in America. The trend of seeing money shift from actively managed funds to passive ETFs shouldn’t come as a surprise, but the magnitude and unabated shift of flows seems to spell the death of the old actively managed mutual […]
Read the full article →